MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke and preeclampsia, announced today that management will be participating in the following investor conferences during September.
- HC Wainwright Global Investment Conference, September 9-11, New York “ Management will present in person on Monday, September 9th at 3:00-3:30 PM ET and participate in one-on-one meetings.
- Lake Street Best Ideas Growth Conference Big 8, September 12, New York “ Management will participate in one-on-one meetings.
Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their respective account representatives to arrange a meeting.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904682546/en/
Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Source: DiaMedica Therapeutics Inc.
